surmount-1 tirzepatide obesity nejm 2022 weight loss percent versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Semaglutide vs. Tirzepatide: Which GLP-1

For many people, weekly injection becomes routine after the first few administrations

Data from randomized controlled trials suggest that withdrawing either glucagon-like peptide-1 (GLP-1) receptor agonists or dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists leads to a substantial regain of lost weight

doi: 10.1073/pnas.2100050118 53 FlorosKVChawlaATJohnson-BerroMOKhatriRStamatouliAMBoikosSAet al

Improves overall health Losing weight and keeping it off can reduce health risks associated with obesity, such as heart disease, diabetes, high blood pressure, and shorter lifespan

The Mechanism of Action Semaglutide works by mimicking a hormone called GLP-1, which is naturally produced in the gut